References
- Kuo G, Choo QL, Alter HJ, et al, An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989; 244: 362–364. [PUBMED], [INFOTRIEVE]
- World Health Organization.. Hepatitis C—global prevalence (update). Wkly Epidemiol Rec, 10, December. 1999; 74: 425–427. [CSA]
- Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep. 1998; 47(RR-19)1–54
- The sentinel counties study of acute viral hepatitis.. CDC Hepatitis Surveillance. 2000, Report number 57..
- Plan and operation of the third National Health and Nutrition Examination Survey (NHANES III), 1988–94. Vital Health Stat 1. 1994; 32
- Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis. 1995; 15: 5–14. [PUBMED], [INFOTRIEVE], [CSA]
- Conry-Cantilena C, VanRaden M, Gibble J, et al, Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med. 1996; 334: 1691–1696. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Alter MJ, Margolis HS, Krawczynski K, et al, The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992; 327: 1899–1905. [PUBMED], [INFOTRIEVE], [CSA]
- Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997; 26, (3 Suppl 1). 62S–65S. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Sharara AI, Hunt CM, Hamilton JD, Hepatitis C. Ann Internal Med. 1996; 125: 658–668. [CSA]
- Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short- term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lympho tropic viruses. Am J Public Health. 1996; 86: 655–661. [PUBMED], [INFOTRIEVE], [CSA]
- Nakagiri I, Ichihara K, Ohmoto K, Hirokawa M, Matsuda N. Analysis of discordant test results among five second-generation assays for anti-hepatitis C virus antibodies also tested by polymerase chain reaction-RNA assay and other laboratory and clinical tests for hepatitis. J Clin Microbiol. 1993; 31: 2974–2980. [PUBMED], [INFOTRIEVE], [CSA]
- McMahon BJ, London T. Workshop on screening for hepatocellular carcinoma. J Nat Cancer Inst. 1991; 83: 916–919. [PUBMED], [INFOTRIEVE]
- Early diagnosis of hepatocellular carcinoma in Italy. A summary of a consensus development conference held in Milan, 16 November 1990 by the Italian Association for the Study of the Liver (AISF).. J Hepatol. 1992; 14: 401–403
- Gupta SB, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. Ann Internal Med. 2003; 139: 46–50
- Chu CW, Hwang SJ, Luo JC, et al, Clinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis. C. J Clin Gastroenterol. 2001; 32: 240–244. [CROSSREF]
- National Institutes of Health Consensus Development Conference Panel. Management of hepatitis. C. Hepatology. 1997; 26(3 Suppl 1)2S–10S
- Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001; 345: 41–52. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Koff RS, Dienstag JL. Extrahepatic manifestations of hepatitis C and the association with alcoholic liver disease. Semin Liver Dis. 1995; 15: 101–109. [PUBMED], [INFOTRIEVE], [CSA]
- Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Internal Med. 2000; 132: 296–305. [CSA]
- Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997; 349: 825–832. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995; 332: 1463–1466. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Service USPH. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Rep. 2001; 50(RR-11)1–52
- Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis. 1995; 15: 41–63. [PUBMED], [INFOTRIEVE], [CSA]
- Ahmed A, Keeffe EB. Treatment strategies for chronic hepatitis C: update since the 1997 National Institutes of Health Consensus Development Conference. J Gastroenterol Hepatol. 1999; 14((Suppl))S12–S18. [PUBMED], [INFOTRIEVE]
- Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht J. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358: 958–965. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Poynard T, Marcellin P, Lee SS, et al, Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998; 352: 1426–1432. [PUBMED], [INFOTRIEVE], [CROSSREF]
- McHutchison JG, Gordon SC, Schiff ER, et al, Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 339: 1485–1492. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Dieterich D. Chronic hepatitis C: update on diagnosis and treatment, Consultant. 2000; 1590–1596
- EASL, International. Consensus Conference on Hepatitis C. Paris, 26-28 February 1999, consensus statement: European Association for the Study of the Liver. J Hepatol. 1999; 30: 956–961. [CROSSREF]
- Nutt AK, Hassan HA, Lindsey J, Lamps LW, Raufman JP. Liver biopsy in the evaluation of patients with chronic hepatitis C who have repeatedly normal or near-normal serum alanine aminotransferase levels. Am J Med. 2000; 109: 62–64. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Jaeckel E CM, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, Manns M. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001; 345: 1452–1457. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Marcellin P, Boyer N, Gervais A, et al, Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Internal Med. 1997; 127: 875–881. [CSA]
- Heathcote EJ, Shiffman ML, Cooksley WG, et al, Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000; 343: 1673–1680. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Zeuzem S, Feinman SV, Rasenack J, et al, Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000; 343: 1666–1672. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Schalm SW, Fattovich G, Brouwer JT. Therapy of hepatitis C: patients with cirrhosis. Hepatology. 1997; 26((3 Suppl 1))128S–132S. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Feray C, Caccamo L, Alexander GJ, et al, European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology. 1999; 117: 619–625. [PUBMED], [INFOTRIEVE], [CSA]
- Wright TL, Donegan E, Hsu HH, et al, Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology. 1992; 103: 317–322. [PUBMED], [INFOTRIEVE]
- Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology. 1997; 26((3 Suppl 1))112S–121S. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol. 1996; 24: 38–47. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ho SB, Nguyen H, Tetrick LL, Opitz GA, Basara ML, Dieperink E. Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population. Am J Gastroenterol. 2001; 96: 157–164. [PUBMED], [INFOTRIEVE]
- Fontana RJ. Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Dig Dis. 2000; 18: 107–116. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol. 1994; 21: 241–243. [PUBMED], [INFOTRIEVE]
- Beeder AB, Millman RB. Treatment of Patients with Psychopathology and Substance Abuse. Baltimore, Williams & Wilkins. 1992
- Musselman DL, Lawson DH, Gumnick JF, et al, Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Medicine. 2001; 344: 961–66. [CROSSREF], [CSA]
- Canadian consensus conference on the management of viral hepatitis. Canadian Association for the Study of the Liver, Can J Gastroenterol. 2000; 14(Suppl B)5B–20B
- Sherman M. Management of viral hepatitis: clinical and public health perspectives—a consensus statement. CASL Hepatitis Consensus Group. Canadian Association for Study of the Liver. Can J Gastroenterol. 1997; 11: 407–416. [PUBMED], [INFOTRIEVE], [CSA]
- National Institute of Diabetes and Digestive and Kidney Diseases. Chronic hepatitis C: current disease management. Available at:. http://digestive.niddk.nih.gov/ddiseases/pubs/ chronichepc/index.htm, Accessed December 9. 2003
- Stephenson J. Former addicts face barriers to treatment for HCV. JAMA. 2001; 285: 1003–1005. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Szabo G. Consequences of alcohol consumption on host defence. Alcohol Alcohol. 1999; 34: 830–841. [PUBMED], [INFOTRIEVE]
- Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend. 2001; 61: 211–215. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Best D, Noble A, Finch E, Gossop M, Sidwell C, Strang J. Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment. BMJ. 1999; 319: 290–291. [PUBMED], [INFOTRIEVE]
- Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology. 2001; 34: 188–193. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend. 2002; 67: 117–123. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- NIH, National. Institutes of Health Consensus Development Conference statement: management of hepatitis C. Available at:. http://consensus.nih.gov/cons/116/091202116cdc_statement.htm, 2002
- Edlin BR, Seal KH, Lorvick J, et al, Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?. N Engl J Med. 2001; 345: 211–215. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kreek MJ, Dodes L, Kane S, Knobler J, Martin R. Long-term methadone maintenance therapy: effects on liver function. Ann Intern Med. 1972; 77: 598–602. [PUBMED], [INFOTRIEVE]
- Lozano Polo JL, Gutierrez Mora E, Martinez Perez V, Santamaria Gutierrez J, Vada Sanchez J, Vallejo Correas JA. Effect of methadone or naltrexone on the course of transaminases in parenteral drug users with hepatitis C virus infection. Revista Clinica Espanola. 1997; 197: 479–483. [PUBMED], [INFOTRIEVE], [CSA]
- Gomez-Lechon MJ, Ponsoda X, Jover R, Fabra R, Trullenque R, Castell JV. Hepatotoxicity of the opioids morphine, heroin, meperidine, and methadone to cultured human hepatocytes. Molecular Toxicology. 1987; 1: 453–463. [PUBMED], [INFOTRIEVE]
- Novick DM, Kreek MJ, Fanizza AM, Yancovitz SR, Gelb AM, Stenger RJ. Methadone disposition in patients with chronic liver disease. Clinical Pharmacology & Therapeutics. 1981; 30: 353–362
- Novick DM, Kreek MJ, Arns PA, Lau LL, Yancovitz SR, Gelb AM. Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients. Alcohol Clin Exp Res. 1985; 9: 349–354. [PUBMED], [INFOTRIEVE]
- Lange WR, Fudala PJ, Dax EM, Johnson RE. Safety and side effects of buprenorphine in the clinical management of heroin addiction. Drug Alcohol Depend. 1990; 26: 19–28. [PUBMED], [INFOTRIEVE], [CSA]
- Petry NM, Bickel WK, Piasecki D, Marsch MA, Badger GJ. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am J Addict. 2000; 9: 265–269. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Berson A, Gervais A, Cazals D, et al, Hepatitis after intravenous buprenorphine misuse in heroin addicts [comment]. J Hepatol. 2001; 34: 346–350. [PUBMED], [INFOTRIEVE], [CROSSREF]
- UNAIDS.Report on the global HIV/AIDS epidemic. World Health Organization, December. 2000
- CDC-NCHSTP-DHAP: HIV/AIDS surveillance Report. Available at:. http://www. cdc.gov/hiv/stats/hasr1202.2000, Accessed December 9. 2003
- HIV prevention strategic plan through 2005—Centers for Disease Control and Prevention (CDC). January 2001. Available at:. http://www.cdc.gov/hiv/partners/PSP/How-Infected.htm, Accessed December 9. 2003
- Palella FJ, Delaney KM, Moorman AC, et al, Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338: 853–860. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Daar ES, Little S, Pitt J, et al, Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med. 2001; 134: 25–29. [PUBMED], [INFOTRIEVE], [CSA]
- Yilmaz G. Diagnosis of HIV infection and laboratory monitoring of its therapy. J Clin Virology. 2001; 21: 187–196. [CROSSREF], [CSA]
- Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med. 1998; 339: 33–39. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Quinn TC. Acute primary HIV infection. JAMA. 1997; 278: 58–62. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996; 125: 257–264. [PUBMED], [INFOTRIEVE], [CSA]
- USPHS/Kaiser. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. November 10, 2003. Available at:. www.aidsinfo.nih.gov/guidelines/ adult/AA_1.11003.pdf, Accessed December 9, 2003..
- More D, O'Brien K, Walter E. Utility of an HIV-1 RNA assay in the diagnosis of acute retroviral syndrome. Southern Medical Journal. 2000; 93: 1004–1006. [PUBMED], [INFOTRIEVE], [CSA]
- Yu K, Daar ES. Primary HIV infection. Current trends in transmission, testing, and treatment. Postgrad Med J. 2000; 107: 114–116, 119–122
- Routy JP, Vanhems P, Rouleau D, et al, Comparison of clinical features of acute HIV-1 infection in patients infected sexually or through injection drug use. The Investigators of the Primary HIV Infection Study. J Acquir Immune Defic Syndr. 2000; 24: 425–432
- Dorrucci M, Rezza G, Vlahov D, et al, Clinical characteristics and prognostic value of acute retroviral syndrome among injecting drug users. Italian Seroconversion Study. AIDS. 1995; 9: 597–604. [PUBMED], [INFOTRIEVE]
- Miller V, Mocroft A, Reiss P, et al, Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med. 1999; 130: 570–577. [PUBMED], [INFOTRIEVE], [CSA]
- Vergis EN, Mellors JW. Natural history of HIV-1 infection. Infect Dis Clin North Am. 2000; 14, v-vi. 809–825. [PUBMED], [INFOTRIEVE], [CSA]
- Mellors JW, Munoz A, Giorgi JV, et al, Plasma viral load and CD4 + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997; 126: 946–954. [PUBMED], [INFOTRIEVE], [CSA]
- Lyles CM, Graham NM, Astemborski J, et al, Cell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men. Eur J of Epidemiol. 1999; 15: 99–108. [CROSSREF], [CSA]
- Lyles CM, Dorrucci M, Vlahov D, et al, Longitudinal human immunodeficiency virus type 1 load in the italian seroconversion study: correlates and temporal trends of virus load. J Infect Dis. 1999; 180: 1018–1024. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Pezzotti P, Galai N, Vlahov D, Rezza G, Lyles CM, Astemborski J. Direct comparison of time to AIDS and infectious disease death between HIV seroconverter injection drug users in Italy and the United States: results from the ALIVE and ISS studies. AIDS Link to Intravenous Experiences. Italian Seroconversion Study. J Acquir Immune Defic Syndr. 1999; 20: 275–282
- Pezzotti P, Phillips AN, Dorrucci M, et al, Category of exposure to HIV and age in the progression to AIDS: longitudinal study of 1199 people with known dates of seroconversion. HIV Italian Seroconversion Study Group. BMJ. 1996; 313: 583–586. [PUBMED], [INFOTRIEVE]
- Mariotto AB, Mariotti S, Pezzotti P, Rezza G, Verdecchia A. Estimation of the acquired immunodeficiency syndrome incubation period in intravenous drug users: a comparison with male homosexuals. Am J Epidemiol. 1992; 135: 428–437. [PUBMED], [INFOTRIEVE], [CSA]
- Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N. Engl J Medicine. 2001; 344: 720–725. [CROSSREF], [CSA]
- Farzadegan H, Hoover DR, Astemborski J, et al, Sex differences in HIV-1 viral load and progression to AIDS. Lancet. 1998; 352: 1510–1514. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD. Long-term HIV-1 infection without immunologic progression. AIDS. 1994; 8: 1123–1128. [PUBMED], [INFOTRIEVE]
- Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. New Engl J Medicine. 1995; 332: 201–208. [CROSSREF], [CSA]
- Petrucci A, Dorrucci M, Alliegro MB, et al, How many HIV-infected individuals may be defined as long-term nonprogressors? A report from the Italian Seroconversion Study. Italian Seroconversion Study Group (ISS). J Acquir Immune Defic Syndr. 1997; 14: 243–248
- NIH. Consensus Development Conference statement: Interventions to prevent HIV risk behaviors. Bethesda, MD: National Institutes of Health; 1997. Available at:. http://consensus.nih.gov/cons/104/104 statement.htm, Accessed December 9. 2003
- CDC. Notice to readers publication of HIV-prevention bulletin for health-care providers regarding advice to persons who inject illicit drugs. MMWR Morb Mortal Wkly Rep.. 1997; 46: 510
- Des Jarlais DC, Marmor M, Friedmann P, et al, HIV incidence among injection drug users in New York City, 1992-1997: evidence for a declining epidemic. Am J Public Health. 2000; 90: 352–359. [PUBMED], [INFOTRIEVE], [CSA]
- Des Jarlais DC, Perlis T, Friedman SR, et al, Behavioral risk reduction in a declining HIV epidemic: injection drug users in New York City, 1990-1997. Am J Public Health. 2000; 90: 1112–1116. [PUBMED], [INFOTRIEVE], [CSA]
- CDC. Healthy People 2010—HIV. Centers for Disease Control and Prevention, Health Resources and Services Administration. Available at:. http://www.health.gov/healthypeople/ document/html/volume1/13hiv.htm, Accessed January 31. 2001
- Katz MH, Gerberding JL. Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use. N Engl J Medicine. 1997; 336: 1097–1100. [CROSSREF], [CSA]
- Lurie P, Miller S, Hecht F, Chesney M, Lo B. Postexposure prophylaxis after non-occupational HIV exposure: clinical, ethical, and policy considerations. JAMA. 1998; 280: 1769–1773. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Management of possible sexual, injecting-drug-use, or other nonoccupational exposure to HIV, including considerations related to antiretroviral therapy. Public Health Service statement. MMWR Morb Mortal Wkly Rep.. 1998; 47(RR-17): 1–14
- O'Connor PG. HIV post-exposure therapy for drug users in treatment. J Subst Abuse Treat. 2000; 18: 17–21. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Vlahov D, Graham N, Hoover D, et al, Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4 + cell count. JAMA. 1998; 279: 35–40. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hughes MD, Johnson VA, Hirsch MS, et al, Monitoring plasma HIV-1 RNA levels in addition to CD4 + lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med. 1997; 126: 929–938. [PUBMED], [INFOTRIEVE], [CSA]
- Paredes R, Mocroft A, Kirk O, et al, Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med. 2000; 160: 1123–1132. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Phillips AN, Staszewski S, Weber R, Kirk O, et al, HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA. 2001; 286: 2560–2567. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, Montaner JSG. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001; 286: 2568–2577. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Rosenberg ES, Altfeld M, Poon SH, et al, Immune control of HIV-1 after early treatment of acute infection. Nature. 2000; 407: 523–526. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Rosenberg ES, Billingsley JM, Caliendo AM, et al, Vigorous HIV-1-specific CD4 + T cell responses associated with control of viremia. Science. 1997; 278: 1447–1450. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Berrey MM, Schacker T, Collier AC, et al, Treatment of primary human immuno- deficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis. 2001; 183: 1466–1475. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lalezari JP, Henry K, O'Hearn M, et al, Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America [comment]. N Engl J Med. 2003; 348: 2175–2185. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Detels R, Munoz A, McFarlane G, et al, Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA. 1998; 280: 1497–1503. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Paterson DL, Swindells S, Mohr J, et al, Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000; 133: 21–30. [PUBMED], [INFOTRIEVE], [CSA]
- Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al, Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society—USA Panel.. JAMA. 2000; 283: 2417–2426. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Baxter JD, Mayers DL, Wentworth DN, et al, A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 2000; 14: F83–93. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Durant J, Clevenbergh P, Halfon P, et al, Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999; 353: 2195–2199. [PUBMED], [INFOTRIEVE], [CROSSREF]
- USPHS/IDSA. Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus, MMWR-Morb Mortal Wkly Report. 2002; 51(RR-8)1–60
- Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med. 2000; 342: 1416–1429. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hadigan CG. S. Insulin resistance in HIV Lipodystrophy Syndrome. AIDS Clinical Care. 2001; 13: 13–19
- Landovitz RJS. P.E. NRTI-associated mitochondrial toxicity. AIDS Clinical Care. 2001; 13: 43–49. [PUBMED], [INFOTRIEVE], [CSA]
- Roca B, Gomez CJ, Arnedo A. Stavudine, lamivudine, and indinavir in drug abusing and non-drug abusing HIV-infected patients: adherence, side effects and efficacy. J Infect. 1999; 39: 141–145. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS. 2001; 15: 1115–1123. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Turner BJ, Fleishman JA, Wenger N, et al, Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. J Gen Intern Med. 2001; 16: 625–633. [PUBMED], [INFOTRIEVE], [CSA]
- Bassetti S, Battegay M, Furrer H, et al, Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 1999; 21: 114–119. [PUBMED], [INFOTRIEVE]
- Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998; 280: 544–546. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Strathdee SA, Palepu A, Cornelisse PG, et al, Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998; 280: 547–549. [PUBMED], [INFOTRIEVE], [CROSSREF]
- O'Connor PG, Selwyn PA, Schottenfeld RS. Medical care for injection-drug users with human immunodeficiency virus infection. N Engl J Med. 1994; 331: 450–459. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- O'Connor PG, Molde S, Henry S, Shockcor WT, Schottenfeld RS. Human immuno- deficiency virus infection in intravenous drug users: a model for primary care. Am J Med. 1992; 93: 382–386. [PUBMED], [INFOTRIEVE], [CROSSREF]
- McCance-Katz EF, Rainey PM, Jatlow P, Friedland G. Methadone effects on zidovudine disposition. AIDS Clinical Trials Group 262. J Acquir Immune Defic Syndr. 1998; 18: 435–443
- Rainey PM, Friedland G, McCance-Katz EF, et al, Interaction of methadone with didanosine and stavudine. J Acquir Immune Defic Syndr: JAIDS. 2000; 24: 241–248
- Rainey PM, Friedland GH, Snidow JW, et al, The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. Am J Addict. 2002; 11: 66–74. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Clarke SM, Mulcahy FM, Tjia J, et al, The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol. 2001; 51: 213–217. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Clarke SM, Mulcahy FM, Tjia J, et al, Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Dis. 2001; 33: 1595–1597. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Iribarne C, Carlhant D, Dreano Y, Picart D, Lohezic F, Riche C. Inhibition of methadone and buprenorphine n-dealkylation by three HIV-1 protease inhibitors. Drug Metabolism and Disposition. 1998; 26: 257–260. [PUBMED], [INFOTRIEVE], [CSA]
- Clarke S, Mulcahy F, Bergin C, et al, Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. Clin Infect Dis. 2002; 34: 1143–1145. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Akerele EO, Levin F, Nunes E, Brady R, Kleber H. Effects of HIV triple therapy on methadone levels. Am J Addict. 2002; 11: 308–314. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- McCance-Katz EF, Rainey PM, Friedland G, Kosten TR, Jatlow P. Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am J Addict. 2001; 10: 296–307. [PUBMED], [INFOTRIEVE], [CSA]
- Carrieri MP, Vlahov D, Dellamonica P, et al, Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. The Manif-2000 Study Group. Drug Alcohol Depend. 2000; 60: 51–54. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS. 2000; 14: 151–155. [PUBMED], [INFOTRIEVE], [CROSSREF]
- CDC. National Hepatitis C Prevention strategy—a comprehensive strategy for the prevention and control of hepatitis C virus infection and its consequences. Division of Viral Hepatitis; National Center for Infectious Diseases. 2001, Available at:. www.cdc.gov/ncidod/diseases/hepatitis/c/plan/strategy.pdf
- Notice to readers: FDA approval for a combined hepatitis A and B vaccine, MMWR Morb Mortal Wkly Report. 2001; 50: 806–807
- Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med. 1997; 336: 196–204
- Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP), MMWR Morb Mortal Wkly Rep. 1991; 40(RR-13)1–25
- Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins for persons with altered immunocompetence, MMWR Morb Mortal Wkly Rep. 1993; 42(RR-4)1–18
- Bridges CB, Fukuda K, Cox NJ, Singleton JA. Prevention and control of influenza, Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2001; 50(RR-4)1–44. [CSA]
- CDC. Update on adult immunization, MMWR Morb Mortal Wkly Rep. 1991; 40(RR-12)
- Tetanus among injecting-drug users—California. 1997, MMWR Morb Mortal Wkly Rep. 1998; 47: 149–151
- Bartlett JG, Gallant JE. Medical Management of HIV Infection. Baltimore, MD, Johns Hopkins University, Division of Infectious Diseases. 2001
- Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000; 30(Suppl 1)S77–84. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Thomas DL, Shih JW, Alter HJ, et al, Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis. 1996; 174: 690–695. [PUBMED], [INFOTRIEVE]
- Bica IM, B Dhar, R. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001; 32: 492–497. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Wyld R, Robertson JR, Brettle RP, Mellor J, Prescott L, Simmonds P. Absence of hepatitis C virus transmission but frequent transmission of HIV-1 from sexual contact with doubly-infected individuals. J Infect. 1997; 35: 163–166. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Eyster ME, Alter HJ, Aledort LM, Quan S, Hatzakis A, Goedert JJ. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med. 1991; 115: 764–768. [PUBMED], [INFOTRIEVE]
- Soto B, Sanchez-Quijano A, Rodrigo L, et al, Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997; 26: 1–5. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Sanchez-Quijano A, Andreu J, Gavilan F, et al, Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis. 1995; 14: 949–953. [PUBMED], [INFOTRIEVE], [CSA]
- Benhamou Y, Bochet M, Di Martino V, et al, Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999; 30: 1054–1058. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Greub G, Ledergerber B, et al, Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV–1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000; 356: 1800–1805. [PUBMED], [INFOTRIEVE], [CROSSREF]
- John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?. AIDS. 1998; 12: 2289–2293. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000; 283: 74–80. [PUBMED], [INFOTRIEVE], [CROSSREF]
- den Brinker M, Wit FW, Wertheim-van Dillen PM, et al, Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000; 14: 2895–2902. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001; 27: 426–431. [PUBMED], [INFOTRIEVE]
- USPHS/Kaiser. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. November 10, 2003. Available at:. www.aidsinfo.nih.gov/guidelines/adult/AA_111003.pdf, Accessed December 9. 2003